Business Description
Pro Medicus Ltd
ISIN : AU000000PME8
Share Class Description:
ASX:PME: Ordinary SharesDescription
Pro Medicus is a healthcare IT company specializing in radiology imaging software. Its main product, Visage 7, is a clinical desktop application that radiologists use to view, enhance, and manipulate images from any device and make a diagnosis. Its main customers are U.S. private academic hospitals. In fiscal 2022, Pro Medicus earned 79% of revenue in North America, 16% from Australia, and the remaining 6% in Europe.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 85.78 | |||||
| Equity-to-Asset | 0.74 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | 0.02 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 9/9 | |||||
| Altman Z-Score | 109.99 | |||||
| Beneish M-Score | -2.21 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 29.9 | |||||
| 3-Year EBITDA Growth Rate | 34.4 | |||||
| 3-Year EPS without NRI Growth Rate | 37.9 | |||||
| 3-Year FCF Growth Rate | 33.4 | |||||
| 3-Year Book Growth Rate | 31.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 34.42 | |||||
| Future 3-5Y Total Revenue Growth Rate | 26.45 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 43.17 | |||||
| 9-Day RSI | 46.62 | |||||
| 14-Day RSI | 49.45 | |||||
| 6-1 Month Momentum % | 22.04 | |||||
| 12-1 Month Momentum % | 55.5 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.49 | |||||
| Quick Ratio | 7.49 | |||||
| Cash Ratio | 5.64 | |||||
| Days Inventory | 49.8 | |||||
| Days Sales Outstanding | 103.17 | |||||
| Days Payable | 4377.17 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.35 | |||||
| Dividend Payout Ratio | 0.45 | |||||
| 3-Year Dividend Growth Rate | 33.5 | |||||
| Forward Dividend Yield % | 0.36 | |||||
| 5-Year Yield-on-Cost % | 1.71 | |||||
| 3-Year Average Share Buyback Ratio | -0.2 | |||||
| Shareholder Yield % | 0.33 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 99.7 | |||||
| Operating Margin % | 67.24 | |||||
| Net Margin % | 49.07 | |||||
| FCF Margin % | 45.67 | |||||
| ROE % | 50.4 | |||||
| ROA % | 35.38 | |||||
| ROIC % | 91.9 | |||||
| ROC (Joel Greenblatt) % | 496.78 | |||||
| ROCE % | 55.97 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 154.61 | |||||
| Forward PE Ratio | 106.38 | |||||
| PE Ratio without NRI | 154.61 | |||||
| Shiller PE Ratio | 483.99 | |||||
| Price-to-Owner-Earnings | 183.43 | |||||
| PEG Ratio | 4.76 | |||||
| PS Ratio | 75.82 | |||||
| PB Ratio | 67.56 | |||||
| Price-to-Tangible-Book | 77.41 | |||||
| Price-to-Free-Cash-Flow | 166.05 | |||||
| Price-to-Operating-Cash-Flow | 150.75 | |||||
| EV-to-EBIT | 110.23 | |||||
| EV-to-Forward-EBIT | 70.71 | |||||
| EV-to-EBITDA | 101.28 | |||||
| EV-to-Forward-EBITDA | 65.84 | |||||
| EV-to-Revenue | 74.11 | |||||
| EV-to-Forward-Revenue | 50.27 | |||||
| EV-to-FCF | 171 | |||||
| Price-to-Projected-FCF | 20.39 | |||||
| Price-to-DCF (Earnings Based) | 4.95 | |||||
| Price-to-DCF (FCF Based) | 5.31 | |||||
| Price-to-Median-PS-Value | 2.96 | |||||
| Price-to-Peter-Lynch-Fair-Value | 7.1 | |||||
| Price-to-Graham-Number | 23.09 | |||||
| Price-to-Net-Current-Asset-Value | 88.76 | |||||
| Price-to-Net-Cash | 139.14 | |||||
| Earnings Yield (Greenblatt) % | 0.91 | |||||
| FCF Yield % | 0.62 | |||||
| Forward Rate of Return (Yacktman) % | 20.28 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Pro Medicus Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil A$) | 142.054 | ||
| EPS (TTM) (A$) | 0.666 | ||
| Beta | 1.75 | ||
| Volatility % | 28.27 | ||
| 14-Day RSI | 49.45 | ||
| 14-Day ATR (A$) | 3.323765 | ||
| 20-Day SMA (A$) | 104.3885 | ||
| 12-1 Month Momentum % | 55.5 | ||
| 52-Week Range (A$) | 58.6 - 111.885 | ||
| Shares Outstanding (Mil) | 104.42 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Pro Medicus Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Pro Medicus Ltd Stock Events
| Event | Date | Price(A$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Pro Medicus Ltd Frequently Asked Questions
What is Pro Medicus Ltd(ASX:PME)'s stock price today?
The current price of ASX:PME is A$102.96. The 52 week high of ASX:PME is A$111.89 and 52 week low is A$58.60.
When is next earnings date of Pro Medicus Ltd(ASX:PME)?
The next earnings date of Pro Medicus Ltd(ASX:PME) is 2024-08-15 Est..
Does Pro Medicus Ltd(ASX:PME) pay dividends? If so, how much?
The Dividend Yield %  of Pro Medicus Ltd(ASX:PME) is 0.35% (As of Today), Highest Dividend Payout Ratio of Pro Medicus Ltd(ASX:PME) was 1.33. The lowest was 0.33. And the median was 0.43. The  Forward Dividend Yield % of Pro Medicus Ltd(ASX:PME) is 0.36%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers